TrialPanorama/Dataset huggingface dataset:
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Randomised Double-blind Placebo-controlled Trial to Evaluate the Impact of Vitamin A on Maternal Mortality in Ghana
Brief Summary: Main objectives: To evaluate the impact of weekly vitamin A supplementation (VAS) to women of reproductive age (15-45 years) on maternal mortality in rural Ghana, and to compare this with the impact on overall mortality.

Hypotheses:

1. Weekly supplementation with vitamin A (7000 µg retinol equivalent \[RE\]) to reproductive age women will reduce maternal deaths by 33%.
2. This impact will be achieved by reductions in both pregnancy-related and non-pregnancy-related deaths.
3. There will be a reduction in non-maternal deaths, similar in size to that in maternal non-pregnancy related deaths.

Outcome measures: Maternal mortality rate, and overall mortality rate. Deaths will be identified through monthly demographic surveillance, and classified as maternal (pregnancy-related, non-pregnancy-related) or non-maternal using verbal autopsies.


Options:
A: Inclusion Criteria:

* Married women of reproductive age
* First pregnancy during time period of trial

Exclusion Criteria:

* Premenarchial girls
* Married women with a previous pregnancy enrolled into the trial
* Previously married women who have moved into the study area
* Single women (never married, widowers)
* Women who are sterilized (or whose husbands are sterilized)
* Menopausal women
B: Inclusion Criteria:

* All women of reproductive age (15 to 45 years) who are permanent residents in any of the 4 districts in rural Ghana (Kintampo, Wenchi, Techiman, and Nkoranza)

Exclusion Criteria:

* There will be no exclusions to participation, except for women who are unable to give their informed consent to join the study
C: Inclusion Criteria:

All the women of child-bearing age (15-44 years) living in the study area (4 100) will be visited monthly to assess early pregnancy and will be invited to participate in the trial.

Exclusion Criteria:

Will be excluded from the study women :

* planning to move outside the district within the 2 years following the start of the trial.
* regularly using a contraceptive method.
* already pregnant at the start of the trial.
D: This study is analyzing samples previously collected from the study "A Trial of Vitamins in HIV Progression and Transmission" (HD32257).

The inclusion criteria in this study was:

* HIV infected women presenting to antenatal care between 12 and 27 weeks of gestation

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Randomised Double-blind Placebo-controlled Trial to Evaluate the Impact of Vitamin A on Maternal Mortality in Ghana
Brief Summary: Main objectives: To evaluate the impact of weekly vitamin A supplementation (VAS) to women of reproductive age (15-45 years) on maternal mortality in rural Ghana, and to compare this with the impact on overall mortality.

Hypotheses:

1. Weekly supplementation with vitamin A (7000 µg retinol equivalent \[RE\]) to reproductive age women will reduce maternal deaths by 33%.
2. This impact will be achieved by reductions in both pregnancy-related and non-pregnancy-related deaths.
3. There will be a reduction in non-maternal deaths, similar in size to that in maternal non-pregnancy related deaths.

Outcome measures: Maternal mortality rate, and overall mortality rate. Deaths will be identified through monthly demographic surveillance, and classified as maternal (pregnancy-related, non-pregnancy-related) or non-maternal using verbal autopsies.


Options:
A: Inclusion Criteria:

* Pregnant women \>-18 years of age with low-risk obstetric

Exclusion Criteria:

* Pregnant women expecting a multiple birth
* Take vitamin A supplements during postpartum apart from study intervention
* Premature birth
* Newborn babies with birth defects and / or other serious diseases
B: Inclusion Criteria:

* Healthy women in Dhaka, Bangladesh
* Lactating women in their 2nd or 3rd month of lactation who are planning to breast-feed at least 6 months
* Breast-feeding only one infant
* Age range 18 to 45 years
* Not pregnant
* Serum retinol concentrations \>0.70 umol/L and \<1.10 umol/L
* Normal concentrations of CRP (\<10 mg/L)
* At least one arm vein deemed adequate for blood collection, as evaluated by a screening nurse.
* Willing to consume the test foods daily 6 d/wk for one month

Exclusion Criteria:

* Health status is not compatible with the inclusion criteria, such as screening blood chemistries indicative of vitamin A deficiency.
* Severe anemia (Hb \<9 mg/dL)
* Current pregnancy
* Must not have known allergy to citrus fruit (tangerines or mandarin oranges) or sweet potatoes
* Must have no obvious psychological or sociological problems-such as alcoholism, drug abuse, or severe and acute mental illness that would influence their ability to sign an inform consent agreement or to participate in study duties and activities
C: Inclusion Criteria:

* Pregnant low-risk obstetric

Exclusion Criteria:

* Premature birth
* Newborn babies with birth defects and / or other serious diseases
D: Inclusion Criteria:

* All women of reproductive age (15 to 45 years) who are permanent residents in any of the 4 districts in rural Ghana (Kintampo, Wenchi, Techiman, and Nkoranza)

Exclusion Criteria:

* There will be no exclusions to participation, except for women who are unable to give their informed consent to join the study

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Randomised Double-blind Placebo-controlled Trial to Evaluate the Impact of Vitamin A on Maternal Mortality in Ghana
Brief Summary: Main objectives: To evaluate the impact of weekly vitamin A supplementation (VAS) to women of reproductive age (15-45 years) on maternal mortality in rural Ghana, and to compare this with the impact on overall mortality.

Hypotheses:

1. Weekly supplementation with vitamin A (7000 µg retinol equivalent \[RE\]) to reproductive age women will reduce maternal deaths by 33%.
2. This impact will be achieved by reductions in both pregnancy-related and non-pregnancy-related deaths.
3. There will be a reduction in non-maternal deaths, similar in size to that in maternal non-pregnancy related deaths.

Outcome measures: Maternal mortality rate, and overall mortality rate. Deaths will be identified through monthly demographic surveillance, and classified as maternal (pregnancy-related, non-pregnancy-related) or non-maternal using verbal autopsies.


Options:
A: Inclusion Criteria:

Children ages 2 months to 8 years with height for age Z-score (HAZ) less than the median for the Parque Universitario community. Be a resident in Brazilian flavela. Child's parent or guardian must sign informed consent.

Exclusion Criteria:

Children exclusively breast-fed. Children who participated in the "hospital study" or any other study with in the past two years. Children with fever \> 102 F at time of screening. Children with systemic disease at the time of screening including but not limited to: shock, meningitis, sepsis, pneumonia, tuberculosis, varicella. Children on antibiotics during screening. Children with siblings from the same household enrolled in this study.
B: Inclusion Criteria:

* Urban area: 6-17-month-old children, presenting for vaccination at a health centre in the study area.
* Rural area: 6-23-month-old children who are missing one or more routine vaccinations when visited by our mobile team.

Exclusion Criteria:

* Normally applied contraindications for receiving vaccinations, including high fever.
* VAS within last month.
C: Inclusion Criteria:

* All women of reproductive age (15 to 45 years) who are permanent residents in any of the 4 districts in rural Ghana (Kintampo, Wenchi, Techiman, and Nkoranza)

Exclusion Criteria:

* There will be no exclusions to participation, except for women who are unable to give their informed consent to join the study
D: Inclusion Criteria:

* Infant receiving OPV and BCG within 48 hr of birth

Exclusion Criteria:

* Mother is less than 18 years of age
* Infant is part of a multiple birth
* Infant will likely not remain in the study area for the next 4 months
* Infant has a condition precluding vaccination
* Infant is unable to breastfeed or drink other fluids
* Birth weight is less than 1.5 kg

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Randomised Double-blind Placebo-controlled Trial to Evaluate the Impact of Vitamin A on Maternal Mortality in Ghana
Brief Summary: Main objectives: To evaluate the impact of weekly vitamin A supplementation (VAS) to women of reproductive age (15-45 years) on maternal mortality in rural Ghana, and to compare this with the impact on overall mortality.

Hypotheses:

1. Weekly supplementation with vitamin A (7000 µg retinol equivalent \[RE\]) to reproductive age women will reduce maternal deaths by 33%.
2. This impact will be achieved by reductions in both pregnancy-related and non-pregnancy-related deaths.
3. There will be a reduction in non-maternal deaths, similar in size to that in maternal non-pregnancy related deaths.

Outcome measures: Maternal mortality rate, and overall mortality rate. Deaths will be identified through monthly demographic surveillance, and classified as maternal (pregnancy-related, non-pregnancy-related) or non-maternal using verbal autopsies.


Options:
A: Inclusion Criteria:

* Normal birth weight: belonging to the study area
* Low birth weight: being born at the national hospital

Exclusion Criteria:

* Overt illness
* Signs of vitamin A deficiency
* Previous BCG vaccination
B: Inclusion Criteria:

* All women of reproductive age (15 to 45 years) who are permanent residents in any of the 4 districts in rural Ghana (Kintampo, Wenchi, Techiman, and Nkoranza)

Exclusion Criteria:

* There will be no exclusions to participation, except for women who are unable to give their informed consent to join the study
C: Inclusion Criteria: Belonging to the study area

Exclusion Criteria:Overt illness, signs of vitamin A deficiency, previous BCG vaccination
D: Inclusion Criteria:

* Infant receiving OPV and BCG within 48 hr of birth

Exclusion Criteria:

* Mother is less than 18 years of age
* Infant is part of a multiple birth
* Infant will likely not remain in the study area for the next 4 months
* Infant has a condition precluding vaccination
* Infant is unable to breastfeed or drink other fluids
* Birth weight is less than 1.5 kg

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Randomised Double-blind Placebo-controlled Trial to Evaluate the Impact of Vitamin A on Maternal Mortality in Ghana
Brief Summary: Main objectives: To evaluate the impact of weekly vitamin A supplementation (VAS) to women of reproductive age (15-45 years) on maternal mortality in rural Ghana, and to compare this with the impact on overall mortality.

Hypotheses:

1. Weekly supplementation with vitamin A (7000 µg retinol equivalent \[RE\]) to reproductive age women will reduce maternal deaths by 33%.
2. This impact will be achieved by reductions in both pregnancy-related and non-pregnancy-related deaths.
3. There will be a reduction in non-maternal deaths, similar in size to that in maternal non-pregnancy related deaths.

Outcome measures: Maternal mortality rate, and overall mortality rate. Deaths will be identified through monthly demographic surveillance, and classified as maternal (pregnancy-related, non-pregnancy-related) or non-maternal using verbal autopsies.


Options:
A: Inclusion Criteria:

* All women of reproductive age (15 to 45 years) who are permanent residents in any of the 4 districts in rural Ghana (Kintampo, Wenchi, Techiman, and Nkoranza)

Exclusion Criteria:

* There will be no exclusions to participation, except for women who are unable to give their informed consent to join the study
B: Inclusion Criteria:

* Normal birth weight: belonging to the study area
* Low birth weight: being born at the national hospital

Exclusion Criteria:

* Overt illness
* Signs of vitamin A deficiency
* Previous BCG vaccination
C: Inclusion Criteria: Belonging to the study area

Exclusion Criteria:Overt illness, signs of vitamin A deficiency, previous BCG vaccination
D: Inclusion Criteria: Infants born to women enrolled in a maternal supplementation trial, alive and less than 30 days of age during a newborn dosing visit Exclusion Criteria: Infants who died before the dose could be administered or infants older than 30 days at the time of dosing

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Single Center Randomized Clinical Trial of the Effects of Acetylcysteine in the Prevention of Postoperative Renal Failure
Brief Summary: The purpose of this study is to determine if Acetylcysteine is effective in preventing renal failure associated with cardiac surgery


Options:
A: Inclusion Criteria:

* Patients at risks for acute tubular necrosis (patients with mechanical ventilation, patients with sepsis, in the post-operative state, with hemodynamic impairment or with previous chronic renal failure.
* Consent form signed

Exclusion Criteria:

* Patients with malignant hypertension
* Patients with systolic BP \> 150 mmHg at enrollment
* Patients with Hb level \> 120g/L
* Patients with acute coronaropathy
* Pregnancy
* Patients with urine output \< 600 ml/12 h
B: Inclusion Criteria:

* All types of cardiac surgery in which cardiopulmonary bypass is used

Exclusion Criteria:

* Age under 18 years
* Life-expectancy \< 6 months
* Emergency operations
* Re-operations within the same admission
C: Inclusion Criteria:

* elective cardiac surgical intervention with an expected CBP duration \>120 minutes

Exclusion Criteria:

* Emergency procedures
* Heart transplantation
* Elective left ventricular assist device (LVAD) implantation
* Pulmonary thromendarterectomy
* Declined informed consent
* Serum creatinine \> 2mg/dl
* Body mass index \< 18
* Age \< 18 years
* Pregnant woman
* Receiving chemotherapy or diagnosed with any disease state (e.g., AIDS) that has produced leukopenia
* Receiving antileukocyte drugs
* Receiving TNF-α Blockers, immunosuppressive drugs (e.g. tocilizumab)
* CRP \> 2mg/dl
* History of Stroke
* Bilirubin \>2mg/dl
D: Inclusion Criteria:

* Pts with baseline chronic kidney disease (eGFR\<60 ml/min/1.73m2)undergoing cardiac surgery

Exclusion Criteria:

* Patients on hemodialysis preoperatively
* IV contrast within 4 days prior to surgery
* Urgent/emergent surgery
* History of renal transplantation

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Single Center Randomized Clinical Trial of the Effects of Acetylcysteine in the Prevention of Postoperative Renal Failure
Brief Summary: The purpose of this study is to determine if Acetylcysteine is effective in preventing renal failure associated with cardiac surgery


Options:
A: Inclusion Criteria:

* Age above 70 years
* Preexisting renal impairment (preoperative serum creatinine level \>120µmol/L
* New York Heart Association class III/IV or Moderate to poor left ventricular dysfunction
* Valve surgery or complex cardiac surgery
* Redo cardiac surgery
* Insulin-dependent diabetes mellitus

Exclusion Criteria:

* Age \<18 years
* Known allergy or hypersensitivity to N-acetylcysteine
* Emergency cardiac surgery
* Planned off-pump cardiac surgery
* Enrolled in conflicting research study
* Known blood-borne infectious disease
* Chronic inflammatory disease on immunosuppression
* Chronic moderate to high dose corticosteroid therapy (\>10mg/d prednisone or equivalent)
* End stage renal disease (serum creatinine \>300µmol/L)
* Patients receiving pre-op IV nitrates
B: Inclusion Criteria:

* Patients admitted to the ICU
* Presenting hypothesion (MAP \< 60mm Hg or the needing to use vasoactive drugs) for at least 30 min in the last 12h before study inclusion

Exclusion Criteria:

* Age lower than 18 years old
* Chronic renal failure
* A known history of allergy to any of the study drugs
* Using n-acetylcysteine to paracetamol overdose
* Pregnant women
* Patients who used iodinated contrast medium
* Hemoglobin less than 6.5 mg/dl
* Cancer patients
C: Inclusion Criteria:

* Age above 70 years
* Preexisting renal impairment (preoperative serum creatinine level \>120µmol/L
* New York Heart Association class III/IV or Moderate to poor left ventricular dysfunction
* Valve surgery or complex cardiac surgery
* Redo cardiac surgery
* Insulin-dependent diabetes mellitus

Exclusion Criteria:

* Age \<18 years
* Emergency cardiac surgery
* Planned off-pump cardiac surgery
* Enrolled in conflicting research study
* Known blood-borne infectious disease
* Chronic inflammatory disease on immunosuppression
* Chronic moderate to high dose corticosteroid therapy (\>10mg/d prednisone or equivalent)
* End stage renal disease (serum creatinine \>300µmol/L)
* Thiamine deficiency will be excluded on medical and dietary history.
D: Inclusion Criteria:

* Pts with baseline chronic kidney disease (eGFR\<60 ml/min/1.73m2)undergoing cardiac surgery

Exclusion Criteria:

* Patients on hemodialysis preoperatively
* IV contrast within 4 days prior to surgery
* Urgent/emergent surgery
* History of renal transplantation

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese(MEGA Study)
Brief Summary: To evaluate the primary preventive effect of low-dose pravastatin against coronary heart disease (CHD) in Japanese hypercholesterolemic patients.


Options:
A: Inclusion Criteria:

* greater than or equal to 18 years of age
* Hyperlipidemia
* Urinary protein

Exclusion Criteria:

* Previous rosuvastatin treatment \< 6 months prior to Visit 1
* Statin intolerance
* Severe hypertension
* Diabetes
B: Inclusion Criteria

* Dyslipidemic participants with Chronic Kidney Disease Stage 3
* For entry into the Treatment Phase (Visit 3), the participant satisfied the following laboratory criteria (measured at the Screening Visit\[s\]):

  * Estimated glomerular filtration rate between 30 and 59 mL/min/1.73 m2 (Chronic Kidney Disease Stage 3) by simplified 4 variable Modification of Diet in Renal Disease formula (this includes a 10 percent variation in the upper limit of estimated glomerular filtration rate that was allowed for the enrollment of participants to account for variability in the creatinine assay).
  * Fasting lipid results following greater than or equal to 12-hour fasting period:
* Triglycerides level greater than or equal to 150 mg/dL,
* High-density lipoprotein cholesterol less than 40 mg/dL for males and less than 50 mg/dL for females, and
* Low-density lipoprotein cholesterol greater than or equal to 130 mg/dL Exclusion Criteria
* Participants with certain chronic or unstable medical conditions.
* Participants with unstable dose of medications or receiving coumarin anticoagulants, systemic cyclosporine, or certain other medications.
* Pregnant or lactating women, or women intending to become pregnant.
* Participants with diabetes mellitus that is poorly controlled.
* Participants of Asian ancestry (having Filipino, Chinese, Japanese, Korean, Vietnamese, or Asian-Indian origin).
C: Inclusion Criteria:

* TC:220～270mg/dl
* Male: 40-70 years old/ female: postmenopausal-70 years old
* \<40kg in weight

Exclusion Criteria:

* FH
* History of CHD(angina, MI, post-PTCA/CABG, etc.)
* History of CVA(stroke, TIA, etc.)
* Underlying malignant tumor
D: Inclusion Criteria:

Men and women age 35-75 who have evident CHD

Exclusion Criteria:

Known hypersensitivity to HMG CO-A reductase therapy, liver disease, evidence of secondary hyperlipidemia

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese(MEGA Study)
Brief Summary: To evaluate the primary preventive effect of low-dose pravastatin against coronary heart disease (CHD) in Japanese hypercholesterolemic patients.


Options:
A: Inclusion Criteria:

* Patients who are going to receive total knee replacement arthroplasty from any cause.
* \< 19 years old

Exclusion Criteria:

* patients with cancer
* Patients receiving anticoagulant agents from any cause
* current statin users
* expecting survival from other co-morbidity \< 1year
* Bed ridden patient
* AST, ALT \> 3times of upper normal limit
* CK\> upper normal limit
* pregnancy
* patients who receives hormone replacement therapy
B: Inclusion Criteria:

* gynecologic tumor scheduled for resection

Exclusion Criteria:

* prior reaction to statins
* renal insufficiency
* liver disease
* h/o alcoholism
* prior h/o DVT or hypercoagulability
* concurrent medications that significantly affect cytochrome P450 3A4
* breast feeding or pregnancy
C: Inclusion Criteria:

* TC:220～270mg/dl
* Male: 40-70 years old/ female: postmenopausal-70 years old
* \<40kg in weight

Exclusion Criteria:

* FH
* History of CHD(angina, MI, post-PTCA/CABG, etc.)
* History of CVA(stroke, TIA, etc.)
* Underlying malignant tumor
D: Inclusion Criteria:

* Provision of informed consent prior to any study specific procedures
* Persons with (initial or recurrent) confirmed symptomatic proximal deep vein thrombosis or pulmonary embolism who after a time period of at least 3 to 12 months are allowed to stop, - or stopped using \< 1 month anticoagulant treatment as indicated by their treating physician
* Persons aged 18 years or above

Exclusion Criteria:

* Persons already using statins or lipid lowering drugs, or any other disallowed concomitant medications (erythromycin, HIV protease inhibitors, or cyclosporine)
* History of statin-induced myopathy, or serious hypersensitivity reaction to other HMG-CoA reductase inhibitors (statins), including rosuvastatin
* Life expectancy less than 6 months
* Pregnant woman or woman with childbearing potential who are not willing to use contraception
* Active liver or kidney disease or dysfunction or muscle disorders
* Unstable medical or psychological condition that interferes with study participation

Answer: C